Ghrelin and Metabolic Surgery by Pournaras, Dimitrios J. & le Roux, Carel W.
Hindawi Publishing Corporation
International Journal of Peptides
Volume 2010, Article ID 217267, 5 pages
doi:10.1155/2010/217267
Review Article
GhrelinandMetabolic Surgery
DimitriosJ. Pournaras1,2 andCarelW.leRoux2
1Department of Bariatric Surgery, Musgrove Park Hospital, Taunton, Somerset TA1 5DA, UK
2Imperial Weight Centre, Imperial College London, London W6 8RF, UK
Correspondence should be addressed to Carel W. le Roux, c.leroux@imperial.ac.uk
Received 16 September 2009; Revised 7 December 2009; Accepted 9 December 2009
Academic Editor: Alessandro Laviano
Copyright © 2010 D. J. Pournaras and C. W. le Roux. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Metabolic surgery is the most eﬀective treatment for morbid obesity. Ghrelin has been implicated to play a role in the success of
these procedures. Furthermore, these operations have been used to study the gut-brain axis. This article explores this interaction,
reviewing the available data on changes in ghrelin levels after diﬀerent surgical procedures.
1.Introduction
Surgical procedures are currently the most eﬀective therapy
for long-term weight loss [1]. Furthermore, some of these
operations lead to the rapid remission of type 2 diabetes in
a weight loss independent manner [2]. The mechanism that
l e a d st os u s t a i n e dw e i g h tl o s sa sw e l la sd i a b e t e sr e m i s s i o n
after bariatric operations remains to be fully elucidated.
However, it is becoming evident that these procedures
modulate the gut-brain axis by altering the anatomy of
the gut and aﬀecting gut hormones [3]. In fact some of
these procedures are now considered suitable models to
study the gut brain axis. The landmark study of Cummings
et al. , which showed a profound suppression of ghrelin
levels following Roux-en-Y gastric bypass, has brought the
interaction of weight loss operations and the gut-brain axis
into focus [4–6].
1.1. Ghrelin. Ghrelin is a 28-amino acid peptide produced
from the fundus of the stomach and the proximal intestine
[5–7]. It is the only known orexigenic gut hormone. Central
and peripheral administration leads to increased food intake
[8, 9]. Ghrelin levels increase prior to meals and are
suppressed postprandially in proportion to the amount of
calories ingested, therefore suggesting a possible role in
meal initiation [10, 11]. The 24-hour proﬁle of ghrelin
increases following diet-induced weight loss supporting
the hypothesis that ghrelin has a role in the long-term
regulation of body weight [4]. Obese individuals have lower
fasting ghrelin levels, and signiﬁcantly reduced postprandial
ghrelin suppression compared to normal weight individuals
[12].
1.2. Metabolic Surgery. Surgical procedures were designed
to promote weight loss by reducing stomach volume
(laparoscopic adjustable gastric banding (LABG), laparo-
scopicsleevegastrectomy(LSG)),malabsorptionofnutrients
(biliopancreatic diversion (BPD), duodenal switch (DS)), or
a combination of both (Roux-en-Y gastric bypass (RYGB)).
It is now known that standard proximal Roux-en-Y gastric
bypass causes only malabsorption of micronutrients and not
of calories, and restriction does not play a major role. A
number of studies have shown that changes in gut hormone
concentrations may partly explain the weight loss following
weight losss surgery.
Furthermore, following these procedures a vast improve-
ment in glycaemic control has been observed. A meta-
analysis reported improved glycaemic control and remission
of type 2 diabetes in 83.8% of patients following gastric
bypassand47.8%followinggastricbanding[2].Thefactthat
these procedures improve manifestations of the metabolic
syndrome, often in a weight-loss independent manner has
led to the development of the concept of metabolic surgery.
In fact a number of scientiﬁc societies have changed their
name in order to include this term.
2.Ghrelinand Roux-en-YGastricBypass
RYGB is the most common metabolic procedure worldwide
[13]. Cummings et al. showed a profound suppression2 International Journal of Peptides
of ghrelin levels (24-hour proﬁle) following RYGB [4].
However, the data published since are inconclusive. Diﬀerent
studies showed a decrease in fasting and postprandial ghrelin
levels [14–21], no change in fasting and postprandial levels
[22–32], and an increase in fasting ghrelin levels after RYGB
[33–37]. The reason for this heterogeneity has not been
elucidated and multiple explanations have been proposed.
Diﬀerences in the methods used for evaluating ghrelin levels
are possible, but unlikely. It has been suggested that even
in the studies reporting an increase in fasting ghrelin levels,
ghrelin does not increase to the extent reported with diet-
induced weight loss or of nonobese individuals [26]. In
a study which investigated the intraoperative changes in
ghrelin during RYGB, the complete division of the stomach
and the formation of a vertical pouch contributed to
the decline in the circulating ghrelin [18]. Moreover, an
intact vagus nerve appears to be required for ghrelin to
have an appetite eﬀect [38]. Technical diﬀerences in the
procedure in regards to preservation of the vagus nerve may
be responsible. Iatrogenic vagal nerve dysfunction caused
intraoperatively might also play a role, as shown by a study
which demonstrated a decrease in ghrelin levels on the ﬁrst
postoperative day after RYGB, followed by an increase to
preoperative levels at 1 month and a further increase at 12
months[35].Analternativetheoryhassuggestedthatthedif-
ferent conﬁguration of the pouch might be responsible [39].
In a vertical pouch, ghrelin producing cells are more likely to
be excluded, compared to a horizontal pouch [40]. Finally,
hyperisulinaemia and insulin resistances are associated with
ghrelin suppression in obese individuals [40]. Therefore,
preoperative diﬀerences as well as diﬀerences in the post-
operative improvement in these parameters may cause this
inconsistency.
3. Ghrelinand BiliopancreaticDiversion
BPD is an operation that does cause malabsorption of
calories. A study on patients prior to and 5 days and 2
months after BPD showed a similar response with an initial
reduction in fasting ghrelin, followed by a return to the
preoperative levels when food consumption resumed to
almost preoperative levels [41]. This ﬁnding supports the
hypothesis that although the primary source of ghrelin is
the gastric mucosa, small intestinal nutrient exposure is
suﬃcient for food-induced plasma ghrelin suppression in
humans and gastric nutrient exposure is not necessary for
this suppression [42]. However, diﬀerent studies have shown
anincrease[43–46]ornochange[36,41,47]inghrelinlevels
after BPD.
A decrease in ghrelin levels has been noted after DS
[48, 49]. In this procedure, the reduction in the stomach
volume is achieved with a sleeve gastrectomy. It is impor-
tant to stress the anatomical diﬀerence between BPD as
described by Scopinaro with horizontal gastrectomy where
the fundus remains intact and gets in contact with nutrients,
w h e r e a si nD St y p ed u o d e n a ls w i t c hw i t hs l e e v eg a s t r e c -
tomy the fundus, the main area of ghrelin production, is
resected.
4.GhrelinandGastricBanding
LAGB has been shown to reduce hunger and increase satiety
[50]. No association with ghrelin levels was demonstrated
in the same study [51]. Schindler et al. showed an increase
in fasting ghrelin accompanied by a paradoxical decrease in
hungerafterLAGBsuggestingthatweightlossisindependent
of circulating plasma ghrelin and relies on changes in
eating behaviour induced by gastric restriction [51]. Further
studies on patients following LAGB demonstrated both
increased fasting ghrelin levels [7, 19, 25, 52–54]a n d
a blunted postprandial suppression of ghrelin [17, 32].
However, we, as well as others, were not able to show any
changes in ghrelin levels after laparoscopic gastric banding
[22, 55–57].
5. Ghrelinand SleeveGastrectomy
LSG is a relatively new bariatric operation which was
designed as a restrictive procedure. Recent studies challenge
this classiﬁcation showing accelerated gastric emptying after
LSG [58]. However, another study of patients undergoing
LSG showed no diﬀerence in gastric emptying compared to
preoperatively and therefore the controversy remains [59].
The fact that the fundus of the stomach, the main location
of ghrelin-producing cells, is excluded in this procedure
led to speculation that ghrelin could play a role in the
mechanism of action. Three studies conﬁrmed a decrease in
fasting ghrelin levels after LSG [54, 57, 60]. A prospective,
double-blind study comparing RYGB and LSG conﬁrmed a
signiﬁcant postprandial suppression of ghrelin postopera-
tively, while there was no change in the RYGB group [30].
In the same study, the marked suppression of ghrelin levels
after LSG was associated with greater appetite reduction
and excess weight loss during the ﬁrst postoperative year
compared to RYGB [30]. An even more recent prospective
randomised comparison of LSG and RYGB conﬁrms that
both operations reduce fasting and meal stimulated ghrelin
levels, signiﬁcantly more so after LSG, so resection of the
fundus has more impact on the ghrelin levels compared to
just bypassing it [61].
6. Conclusion
The role of ghrelin in the success of bariatric and metabolic
surgery remains to be further elucidated. Some of the
ﬁndings of the initial studies have not been conﬁrmed in
more recent investigations. Diﬀerent gut hormones as well
as having an incretin eﬀect have been implicated to be
key players in appetite control. However, the hypothesis
that ghrelin might play a role in the mode of action of
metabolic surgery has been crucial in the development
of the ﬁeld. The weight loss as well as the remission of
type 2 diabetes experienced after metabolic surgery is not
exclusively attributed to pure restriction or malabsorption
any more. A lot of research is focused on exploring the
hormonal and metabolic changes after metabolic surgery as
well as the mechanism of action.International Journal of Peptides 3
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